Context Therapeutics Analyst Ratings
Context Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/11/2023 | 344.44% | Maxim Group | → $4 | Initiates Coverage On | → Buy |
| 06/06/2023 | — | HC Wainwright & Co. | Reiterates | → Neutral | |
| 03/23/2023 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 02/07/2023 | 344.44% | HC Wainwright & Co. | → $4 | Reiterates | → Buy |
| 02/02/2022 | 566.67% | HC Wainwright & Co. | → $6 | Initiates Coverage On | → Buy |
| 01/24/2022 | 1011.11% | ThinkEquity | → $10 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/11/2023 | 344.44% | Maxim集团 | →$4 | 开始承保 | →购买 |
| 06/06/2023 | - | HC Wainwright公司 | 重申 | →中性 | |
| 03/23/2023 | - | HC Wainwright公司 | 评级下调 | 购买→中性 | |
| 02/07/2023 | 344.44% | HC Wainwright公司 | →$4 | 重申 | →购买 |
| 02/02/2022 | 566.67% | HC Wainwright公司 | →$6 | 开始承保 | →购买 |
| 01/24/2022 | 1011.11% | ThinkEquity | →$10 | 开始承保 | →购买 |
What is the target price for Context Therapeutics (CNTX)?
Context Treeutics(CNTX)的目标价格是多少？
The latest price target for Context Therapeutics (NASDAQ: CNTX) was reported by Maxim Group on September 11, 2023. The analyst firm set a price target for $4.00 expecting CNTX to rise to within 12 months (a possible 344.44% upside). 4 analyst firms have reported ratings in the last year.
Maxim Group于2023年9月11日报道了Context Treateutics(纳斯达克：CNTX)的最新目标价。这家分析公司将目标价定为4美元，预计CNTX将在12个月内上涨(可能上涨344.44%)。去年有4家分析公司公布了评级。
What is the most recent analyst rating for Context Therapeutics (CNTX)?
Context Treeutics(CNTX)的最新分析师评级是什么？
The latest analyst rating for Context Therapeutics (NASDAQ: CNTX) was provided by Maxim Group, and Context Therapeutics initiated their buy rating.
上下文治疗公司(纳斯达克代码：CNTX)的最新分析师评级是由Maxim集团提供的，而上下文治疗公司启动了他们的买入评级。
When is the next analyst rating going to be posted or updated for Context Therapeutics (CNTX)?
Context Treeutics(CNTX)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Context Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Context Therapeutics was filed on September 11, 2023 so you should expect the next rating to be made available sometime around September 11, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Context Treeutics的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Context治疗公司的上一次评级是在2023年9月11日提交的，所以你应该预计下一次评级将在2024年9月11日左右提供。
Is the Analyst Rating Context Therapeutics (CNTX) correct?
分析师对Context Treeutics(CNTX)的评级正确吗？
While ratings are subjective and will change, the latest Context Therapeutics (CNTX) rating was a initiated with a price target of $0.00 to $4.00. The current price Context Therapeutics (CNTX) is trading at is $0.90, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的上下文治疗(CNTX)评级是以0.00美元至4.00美元的目标价启动的。目前上下文治疗公司(CNTX)的交易价格为0.9美元，在分析师的预测范围内。